This therapy utilizes a sequence-specific short-chain RNA (referred to as a siRNA), which is designed to target and interfere with Ebola virus to make it harmless. One advantage of this approach is the ability to quickly change to a different Ebola virus strains.

Galveston Medical Branch professor of Microbiology and Immunology, University of Texas Thomas Geisbert said: “We will soon adopt a candidate therapy to target the Ebola virus outbreak strain Makona in 3 days after infection. Started this treatment can protect all of our non-human primates against infection of Ebola virus Makona lethal. By this time, those infected animals show clinical symptoms of the disease, the virus can be detected in the blood. ”

In all infected animals showed symptoms of advanced disease, those treated animals showed only minor symptoms, and can be completely recovered. Untreated control animals and in the eighth day of the ninth day die from this disease, which is associated with the patient began to show symptoms of Ebola reported very similar.

This treatment also prevents Ebola virus infection in the liver and kidney damage and blood disorders appear. The results show that, in addition to providing effective control of the survival rate and the level of the virus outside the body, this treatment may also provide protection.

2014, an outbreak of the Ebola virus outbreak in West Africa, resulting in the death of nearly ten thousand people, attracted worldwide attention. Africa’s population was due to rapidly rising trend in the frequency of human contact with the natural reservoir of the Ebola virus is also raising, the future is very likely outbreak similar disaster again.

Dr. Mark Murray, CEO and president of Tekmira Pharmaceuticals, said: “This study confirms that we can quickly and accurately using our siRNA-LNP technology to target a new outbreak of Ebola virus genetic sequence that appears.”

Errors led to an “unreasonable delay” in diagnosing cancer in a woman who later died after the disease recurred following surgery, a watchdog has said.

The GP practice in the NHS Highland health board area has not been named. In the SPSO report, the patient has also not been identified and was described only as Mrs A. A complaint was made to the watchdog on behalf of her family following her death

Mrs A had breast cancer surgery in late 2012, during which an “extremely large high-grade tumour” was removed. The complaint alleged delays in diagnosing cancer. Seven months after having surgery, Mrs A contacted the practice about back pain and spasms. She also had a wheeze and cough.

Between 29 July 2013 and 19 August 2013 she had four telephone consultations with three GPs at the practice, who prescribed and adjusted pain relief medication. They later provided Mrs A with an inhaler. The day after the last consultation she contacted NHS 24 because she was having problems breathing.

It has also said the complaint should be discussed during the next annual appraisals of three GPs involved. NHS Highland said: “We’re aware of the report published today by the ombudsman. “This is for the GP practice to respond to and we would expect them to fully comply with all recommendations laid out in the report.”

The number of breast cancer cases in American women is expected to jump 50% by 2030, according to a study by researchers from the National Cancer Institute (NCI).

The increase is driven mostly by a marked increase in estrogen receptor (ER)-positive tumors and in the number of cases in women older than 70 years.

The NCI team used data from the Surveillance, Epidemiology, and End Results (SEER) Program, population projections from the US Census Bureau, and mathematical models to forecast the number of breast cancer cases in the United States from 2011 to 2030. Such forecasts “could help the oncology community develop a proactive roadmap to optimize prevention and treatment strategies,” they note in a meeting abstract.

In contrast, the researchers forecast that the proportion of ER-negative cancers, both invasive and in situ, will drop from 17% of all tumors in 2011 to 9% in 2030.

This research was supported by the Intramural Research Program of the National Institutes of Health. Dr Rosenberg has disclosed no relevant financial relationships.

American Association for Cancer Research (AACR) 2015 Annual Meeting: Abstract 1850. Presented April 20, 2015.